Organic anion transporters (OATs) play an essential role in the elimination of numerous endogenous and exogenous organic anions from the body. The renal OATs contribute to the excretion of many drugs and their metabolites that are important in clinical medicine. Several families of multispecific organic anion and cation transporters, including OAT family transporters, have recently been identified by molecular cloning. The OAT family consists of six isoforms (OAT1 -4, URAT1, and rodent Oat5) and they are all expressed in the kidney, while some are also expressed in the liver, brain, and placenta. The OAT family represents mainly the renal secretory and reabsorptive pathway for organic anions and is also involved in the distribution of organic anions in the body, drug-drug interactions, and toxicity of anionic substances such as nephrotoxic drugs and uremic toxins. In this review, current knowledge of and recent progress in the understanding of several aspects of OAT family members are discussed.
Introduction
A variety of endogenous and exogenous substances that are harmful to the body can be classified into organic anions and cations. Their elimination is essential for the maintenance of homeostasis. Excretory organs such as the kidneys, liver, and intestine defend the body against potentially harmful effects of these compounds by biotransformation into less active metabolites and by the excretory transport process. In the kidney, drugs and environmental toxicants are eventually excreted into the urine, either in an unchanged form or as biotransformation products. This renal excretion is closely related to physiological events occurring in nephrons, i.e., filtration, secretion, and reabsorption. It was observed more than 70 years ago that phenolsulphophthalein, an anionic dye, was highly concentrated in renal convoluted tubules, suggesting a tubular secretion process (1) . Transport systems responsible for renal tubular secretion of endogenous or exogenous substances have been divided into organic anion and organic cation transport systems based on their preferential substrate selectivity (2) . The process of secreting organic anions and cations through proximal tubular cells is achieved via unidirectional transcellular transport, involving the uptake of organic ions into the cells from the blood across the basolateral membrane followed by extrusion across the brush-border membrane into the proximal tubular fluid (3) . During the last decade, several families of multispecific organic anion transporters, including organic anion transporter (OAT) family (Table 1) , organic anion-transporting polypeptide (oatp) family, sodiumphosphate transporter (NPT) family, and peptide transporter (PEPT) family, has been identified by molecular cloning (Fig. 1 ). Additional findings also suggested ATP-dependent organic anion transporters such as multidrug resistance-associated protein (MRP) as efflux pumps (Fig. 1 ). This review focuses on the recent progress in the understanding of various aspects of the OAT family. A number of reviews (4 -9) on organic anion transporters are available.
General characteristics of OATs

Organic anion transport systems
Substrates for the renal organic anion transport system include a number of chemically heterogeneous weak acids with a carbon backbone and a net negative charge at physiological pH (pK a <7). Their structures may be aromatic or aliphatic. Historically, p-aminohippurate (PAH) has been used as a prototypical substrate for the renal organic anion transport system (2) . PAH is a high-affinity substrate and is almost completely extracted by the renal organic anion transport system during a single pass through the kidney when its serum concentration is low. Thus, PAH clearance has been used to estimate renal plasma flow, and the renal organic anion transporter has been alternatively called PAH transporter. A prominent feature of the PAH transporter is that it interacts with and transports a variety of organic anions with unrelated chemical structures (2 -4) . Various endogenous organic anions, uremic substances, drugs, and environmental compounds have been assumed to be substrates of the PAH transporter. The multispecificity of the PAH transporter is suitable for elimination of a variety of endogenous metabolites and xenobiotics; and in renal physiology, the PAH transport system has been regarded as a representative of "tubular secretion". In 1997, the PAH transporter was isolated by several groups using expression cloning methods and designated OAT1 (organic anion transporter 1) (10 -12) . Subsequently, several organic aniontransporting proteins have been identified at both sides of the renal proximal tubules and our knowledge of organic anion transporter systems has been increased ( Fig. 1 ).
Functional characteristics of organic anion transport systems
In the kidney, the secretion of organic anions takes place in the proximal tubular epithelial cells via at least two steps. The first step is the transport of organic anions from the peritubular plasma across the basolateral membrane into proximal tubular cells. The transport of PAH across the basolateral membrane of proximal tubular cells against the electrochemical gradient occurs in exchange for intracellular dicarboxylates such as αketoglutarate (13) . Two organic anion transporters, OAT1 (10 -12) and OAT3 (14) , have been proposed to be responsible for this step. The second step is the exit of organic anions across the apical membrane at the tubular epithelial cells into the urine. Although this process is energetically downhill for organic anions, it has been believed that this process is also mediated by specific transporters. The luminal efflux system for PAH has been investigated mostly using brush border membrane vesicles. In dogs and rats, anion exchange mechanisms have been demonstrated for the luminal efflux systems (15) . They mediate probenecid-sensitive electroneutral exchange of anionic compounds, including both organic (e.g., PAH, urate, and lactate) and inorganic (e.g., Cl − , HCO 3 − , OH − ) anions. A distinct efflux system involving voltage-driven transport was demonstrated in the pig and rabbit (15) . PAH transport at the apical membrane in the OK kidney epithelial cell line was shown to be mediated by a voltage-driven transport system but not by an anion exchange system (16) . In physiological conditions, a major component of the exit path of organic anions from renal proximal tubular cells has been proposed to be the facilitated diffusion along the electrochemical potential gradient (3, 17) . Voltagedriven organic anion transport plays an important role in this step. However, the molecular nature and precise functional properties of these efflux systems were unknown for a long time.
Molecular identification of OATs
OAT1: Several research groups have cloned the first member of the OAT family, OAT1 (10 -12) . OAT1 mRNA is expressed predominantly in the kidneys and weakly in the brain. In the kidneys, OAT1 protein is localized at the basolateral membrane of proximal tubular cells. OAT1-mediated uptake of PAH is stimulated by an outwardly directed concentration gradient of dicarboxylates such as α-ketoglutarate, which is consistent with the previous notion that OAT1 is an organic anion-dicarboxylate exchanger (13) . The substrate selec-tivity of OAT1 is markedly broad, and substrates include endogenous substances such as dicarboxylates, cyclic nucleotides, and prostaglandins and exogenous substances such as various anionic drugs and environmental compounds (15) . The affinities of OAT1 for these compounds are similar to reported values for the basolateral PAH transporter (2) , and the functional properties and localization of OAT1 are identical to those of the renal PAH transport system.
OAT2: OAT2 was isolated originally from the rat liver as a novel liver-specific transport protein with unknown function (18) . Because of its structural similarities to OAT1, OAT2 was functionally characterized (19) . OAT2 is expressed predominantly in the liver and weakly in the kidneys. Typical substrates of OAT2 are salicylate, acetylsalicylate, prostaglandin E 2 (PGE 2 ), dicarboxylates, and PAH. Transport of tetracycline by hOAT2 as well as other hOATs has been also reported by us (20) . Recently, hOAT2 was proposed to be a sodium-independent multi-specific organic anion / dimethyldicarboxylate exchanger (21) .
OAT3: OAT3 was isolated from the rat (14) , and it seems to us structurally identical to Roct, which has been identified as a transporter-like protein that exhibits a reduced expression in osteosclerosis mice (22) . OAT3 mRNA is expressed in the kidneys, liver, brain and eyes (14) . In the kidneys, OAT3 is localized at the basolateral membrane of proximal tubular cells (23, 24) . In the brain, OAT3 is localized at the brush border membrane of choroid plexus cells (25, 26) and in capillary endothelial cells (27) . Like OAT1, OAT3 recognizes a broad spectrum of substrates, and it mediates the high-affinity transport of PAH, estrone sulfate, ochratoxin A, and various drugs, including the cationic drug cimetidine, in exchange for dicarboxylates inside cells (28, 29) .
OAT4: OAT4 was cloned from human kidneys (30) . OAT4 mRNA is expressed in the kidneys and is localized at the apical membrane of proximal tubular cells. In the placenta, OAT4 is expressed on the foetal side of syncytiotrophoblast cells (31) . When expressed in Xenopus oocytes, OAT4 mediates the Na + -independent, high-affinity transport of estrone sulfate, dehydroepiandrosterone sulfate, ochratoxin A, and PGE 2 and PGF 2α . We recently reported that OAT4 is not a facilitated transporter but an organic anion / dicarboxylate exchanger and that it mediates bidirectional organic anion transport (32) . The results indicate that OAT4 is a renal apical organic anion / dicarboxylate exchanger and mainly serves as a tubular reabsorptive pathway for some organic anions, including sulfate conjugates, driven by an outwardly directed gradient of dicarboxylates such as α-ketoglutarate. However, it seems unlikely that two exchangers of the same type existing in both sides of membranes lead to the vectorial transport of organic anions. These different transport characteristics may contribute to the effective function of the organic anion transport at both sides without any interference from each other.
URAT1: URAT1 (urate/ anion exchanger) is expressed exclusively in the kidneys, where it is located in the apical membrane of proximal tubular cells (33) . URAT1 exhibits Na + -independent uptake of urate and regulates the serum urate level; genetic defects in URAT1 are the predominant causes of idiopathic renal hypouricemia. In a study using URAT1 cRNA-injected Xenopus oocytes, cis-inhibitory effects of uricosuric drugs (e.g., probenecid, benzbromarone, sulfinpyrazone, losartan) and trans-stimulatory effects of anti-uricosuric drugs (e.g., pyrazinoic acid, the metabolite of the antituberculous agent pyrazinamide) on the URAT1mediated transport of urate were demonstrated (33).
Novel aspects of OATs
Novel transport substrates
Although about 10 years have passed since the discovery of OAT1, information regarding novel transport substrates of OAT family members is still increasing. The following substrates have been recently identified and well characterized in terms of OATs' roles in physiology and pathophysiology.
Neurotransmitter metabolites: Acidic metabolites of neurotransmitters derived from dopamine, epinephrine, norepinephrine, and serotonin have been suggested to be endogenous substrates of OAT3, the mRNA expression of which has been detected in the rat brain following its discovery in 1999 (14) . Recently, we elucidated the expression of hOAT1 and hOAT3 in the choroid plexus of the human brain and their interactions with neurotransmitter metabolites using stable cell lines (34) . Immunohistochemical analysis revealed that hOAT1 and hOAT3 are expressed in the cytoplasmic membrane and cytoplasm of the human choroid plexus. Neurotransmitter metabolites, namely, 5-methoxyindole-3acetic acid (5-MI-3-AA), homovanillic acid (HVA), vanilmandelic acid (VMA), 3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindole-3-acetic acid (5-HI-3-AA), N-acetyl-5-hydroxytryptamine (NA-5-HTT), melatonin, 5-methoxytryptamine (5-MTT), 3,4-dihidroxymandelic acid (DHMA), 5-hydroxytryptophol, and 5methoxytryptophol (5-MTP) at 2 mM, inhibited PAH uptake mediated by hOAT1. On the other hand, melatonin, 5-MI-3-AA, NA-5-HTT, 5-MTT, 5-MTP, HVA, 5-HI-3-AA, VMA, DOPAC, 5-hydroxytryptophol, and methanephrine (MN) at 2 mM inhibited estrone sulfate uptake mediated by hOAT3. hOAT1 and hOAT3 mediated the transport of VMA but not that of HVA and melatonin. It is thought that hOAT1 and hOAT3 are involved in the efflux of various neurotransmitter metabolites from the cerebrospinal fluid to blood across the choroid plexus.
Although we could not observe HVA transport via hOAT3, Mori et al. revealed that rOat3 is the brain-toblood HVA efflux transporter at the rat blood-brain barrier (BBB) (35) . rOat3-expressing oocytes exhibited [ 3 H]HVA uptake (K m = 274 µM), which was inhibited by several organic anions, such as PAH, indoxyl sulfate, octanoic acid, and metabolites of monoamine neurotransmitters. Immunohistochemical analysis suggested that rOat3 is localized at the abluminal membrane of brain capillary endothelial cells. The results of Mori et al. provide the first evidence that rOat3 is expressed at the abluminal membrane of the rat BBB and is involved in the brain-to-blood transport of HVA. They suggested that this HVA efflux transport system is likely to play an important role in controlling the level of HVA in the central nervous system (CNS). Similar localization in brain capillary endothelial cells and uptake of [ 3 H]HVA in mouse Oat3 were reported by Ohtsuki et al. (36) .
Bahn et al. demonstrated that OAT1 and OAT3 are involved in the secretion of bioactive tryptophan metabolites from the body (37) . Tryptophan metabolites such as kynurenate (KYNA), xanthurenate (XA), and quinolinate are considered to be important for many physiological processes, especially brain function. Many of these metabolites are secreted with urine. Six tryptophan metabolites, including the bioactive substances KYNA, XA, and the serotonin metabolite 5hydroxyindol acetate, inhibited [ 3 H]PAH or 6-carboxyfluorescein (6-CF) uptake by 50% -85%, demonstrating that these compounds interact with Oat1 as well as with Oat3. The IC 50 of KYNA for mOat1 was 34 µM and that for mOat3 was 8 µM, and the IC 50 of XA for mOat1 was 15 µM and that for mOat3 was 11.5 µM. Quinolinate slightly but significantly inhibited [ 3 H]PAH uptake by mOat1 and had no effect on 6-CF uptake by mOat3. In the mouse brain, Oat1 was found to be expressed in neurons of the cortex cerebri and hippocampus as well as in the ependymal cell layer of the choroid plexus. Therefore, OAT1 and OAT3 are crucial for the regulation of CNS tryptophan metabolite concentration.
Antimetabolites: Thiopurines are used as antileukemic drugs. During chemotherapy CNS relapses occur due to the proliferation of leukemic cells in the CNS resulting from restricted drug distribution in the brain. The molecular mechanism for this limited cerebral distribution remains unclear. Mori et al. reported that rOat3 is involved in the brain-to-blood transport of thiopurines at the BBB and is one of the mechanisms of limited cerebral distribution (38) . rOat1 and rOat3 exhibited [ 14 C]6-MP uptake (K m = 98 µM for rOat1, 50.5 µM for rOat3). rOAT3-mediated [ 14 C]6-MP uptake was also inhibited by other thiopurine derivatives. Although methotrexate inhibited rOAT3-mediated [ 14 C]6-MP uptake, the K i value was 17.5-fold greater than the estimated brain concentration of methotrexate in patients receiving chemotherapy. Accordingly, 6-MP would undergo efflux transport by OAT3 from the brain without any inhibitory effect from coadministered methotrexate in chemotherapy. The results of Mori et al. may provide a molecular basis for improving the permeability of thiopurine nucleobase analogs to the brain and offer an approach to reduce CNS relapses during treatment of patients with ALL. The identification of 6-MP and another antimetabolite, 5-fluorouracil (5-FU), as novel transport substrates for mOat3 was also reported by Kobayashi et al. (39) . K m for 6-MP was 4.01 µM and that for 5-FU was 53.9 nM.
AMPA receptor antagonist:
The major elimination route for zonampanel is by urine via the kidneys. Hashimoto et al. elucidated the molecular mechanism of the renal excretion of zonampanel using cells stably expressing hOAT1, hOAT2, hOAT3, and OAT4 as well as human organic cation transporter (hOCT) 1 and hOCT2 (40) . A time-and concentrationdependent increase in [ 14 C]zonampanel uptake was observed in cells expressing hOAT1, hOAT3, and OAT4. Kms for hOAT1, hOAT3, and OAT4 were 1.4, 7.7, and 215 µM, respectively. These results suggest that the efficient urinary excretion of zonampanel is due to the renal tubular secretion mediated by the organic anion transporters hOAT1, hOAT3, and OAT4.
Xanthine-related compounds: Caffeine (1,3,7-trimethylxanthine, 1,3,7-TMX) is daily and widely consumed in beverages and food and is mainly metabolized to paraxanthine (1,7-dimethylxanthine, 1,7-DMX) and 1-methylxanthine (1-MX). One-third of 1-MX is excreted unchanged into urine, and the remainder undergoes hydroxylation to 1-methyluric acid. Rengelshausen et al. investigated the effect of caffeine and its main metabolites on hOAT1 using Chinese hamster ovary (CHO) cells overexpressing hOAT1 (41) . The uptake of 6-CF into CHO-hOAT1 cells was significantly inhibited by 1-MX (100 µM). 1-MX (500 µM) was equieffective to 100 µM probenecid. In contrast, caffeine and 1,7-DMX did not inhibit the transport of 6-CF at concentrations up to 500 µM. Thus, the caffeine metabolite 1-MX inhibits the transport activity of hOAT1 in vitro.
Because of the wide consumption of caffeine, an inhibitory effect of its metabolite 1-MX on renal tubular secretion mediated by hOAT1 might contribute to the pharmacokinetic variability of drugs such as methotrexate.
Sugawara et al. further examined the inhibitory effects of xanthine-and uric acid-related compounds on the transport of PAH using CHO-K1 cells stably expressing hOAT1 from the aspect of the structure-affinity relationship (42) . The order of potency for the inhibitory effects of xanthine-related compounds on PAH uptake was 1-methyl derivative > 7-methyl derivative > 3methyl derivative = xanthine > 1,3,7-trimethyl derivative (caffeine). The order of potency of the inhibition was 1,3,7-trimethyluric acid > 1,3-dimethyluric acid > 1,7-dimethyluric acid > 1-methyluric acid > uric acid. A significant correlation between inhibitory potency and lipophilicity of the tested uric acid-related compounds was observed. The main determinant of the affinity of xanthine-related compounds is the position of the methyl group. On the other hand, lipophilicity is the main determinant of the affinity of uric acid-related compounds.
HMG-CoA reductase inhibitor: It was recently demonstrated that pravastatin is a relatively specific inhibitor of rOat3 rather than rOat1 (43) . Pravastatin, a structural analog of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA), is a competitive inhibitor of HMG-CoA reductase and therefore blocks the synthesis of cholesterol in the liver. We have elucidated the interactions of human and rat organic anion transporters (hOATs and rOats) with pravastatin (44) . Pravastatin inhibited hOAT1 / rOat1, hOAT2 / rOat2, hOAT3 / rOat3, and OAT4. The mode of inhibition was noncompetitive for hOAT1 and hOAT2, whereas it was competitive for hOAT3 and hOAT4. The effects of OAT inhibitors on OAT1, OAT2, and OAT3 exhibited some but not so remarkable interspecies differences between humans and rats. These results would be useful for the extrapolation of results of the functional analysis of rat organic anion ransport using OAT inhibitors in humans.
Nicotinate: Recently, we demonstrated nicotinate transport via URAT1 in a Xenopus oocyte system (33) . Nicotinate has been used as a lipid-lowering agent producing beneficial changes in serum lipids for atherosclerosis regression. Although inhibitory effects of nicotinate on the synthesis and secretion of VLDL in the liver have been reported, its hepatic transport mechanism was still unknown. We examined, by using cells stably expressing hOAT2, the possibility that hepatic OAT isoform OAT2 functions as an entrance pathway for nicotinate in the liver (45) . hOAT2 mediated a time-and concentration-dependent uptake of nicotinate. hOAT2-mediated nicotinate uptake showed structural specificity and was inhibited by some organic anions such as ICG, glibenclamide, and probenecid and by some NSAIDs (salicylic acid, diclofenac, ketoprofen, indomethacine, and ibuprofen). Identification of the hepatic nicotinate transporter will contribute to the understanding of the molecular basis of drug-drug interactions such a as salicylate-induced increase in serum nicotinate level.
Novel OAT isoforms
Oat5: Oat5 was recently identified from the mouse (46) and rat (47) . It is expressed exclusively in the kidneys, and rat Oat5 is localized at the apical side of the late segment of proximal tubules (47) . Oat5 mediates the transport of steroid sulfates as well as ochratoxin A. Mouse Oat5 (46) and rat Oat5 (47) are functional and not identical to non-functional human OAT5 reported by Sun et al. (48) . The most surprising finding of our study is that rOat5 interacted not only with the five-carbon dicarboxylate α-ketoglutarate (C5) but also with the four-carbon dicarboxylate succinate (C4), which has not been reported as a counterion for the classical renal organic anion transport system to mediate organic anion / succinate exchange (47) . In contrast, the basolateral OAT isoform OAT3 did not exhibit the interaction to succinate. These findings indicate that rOat5 is the renal organic anion transporter that may mainly function as an apical pathway for the reabsorption of some organic anions driven by an outward gradient of both α-ketoglutarate and succinate. It seems appropriate that the apical isoforms of OAT utilize C4 succinate as a counterion, whereas the basolateral OATs utilize C5 αketoglutarate as a counterion, to separate the transport of organic anions at both sides of proximal tubular cells (Fig. 2) . This idea is supported by results showing that the apical membrane isoform OAT4-mediated transport was inhibited by succinate as well as glutarate (P. Jutabha, et al., unpublished observation). Interestingly, urate transport via the urate / anion exchanger (URAT1) localized at the renal apical membrane was also inhibited by succinate at a millimolar concentration in the Xenopus oocyte system (33) . It is thought that succinate exchange in addition to α-ketoglutarate exchange is a common mechanism for the apical membrane isoforms of OAT family members.
Oat6: This putative organic anion transporter was recently isolated (49) . Oat6 is expressed predominantly in the mouse olfactory mucosa but not in the kidneys or brain. Oat6 expression is also observed in the testes. The genomic localization of Oat6 is proximal to the Oat1 / Oat3 gene pair. Based on sequence homologies, this protein was designated Oat6. However, further studies are needed to determine its substrate specificity and therefore its involvement in the transport of organic anions.
OAT7: We identified a novel organic anion transporter, OAT7, exclusively expressed in the human liver. OAT7 showed 35% to 46% identities to those of other members of the OAT family (50) . When expressed in Xenopus oocytes, OAT7 mediated high-affinity transport of sulfate-conjugated steroid hormones, estrone sulfate (K m = 8.7 µM) and DHEA sulfate (K m = 2.2 µM), in a sodium-independent manner, whereas it did not transport other organic anions. Estrone sulfate transport mediated by OAT7 was inhibited by negatively charged BSP, ICG, and several sulfate-conjugated xenobiotics. In contrast, glucuronide and glutathione conjugates exhibited no inhibitory effects on OAT7-mediated transport. Immunohistochemical analysis revealed that OAT7 protein was located in the sinusoidal membrane of hepatocytes.
Oat8: We identified a cDNA encoding a novel multispecific organic anion transporter (designated Oat8) from a rat kidney cDNA library (51) . Oat8 showed 37% to 47% identities to other OAT family members. Oat8 mRNA is expressed exclusively in the kidney. When expressed in Xenopus oocytes, Oat8 mediated transport of sulfate conjugates of steroids such as estrone sulfate and DHEAS in a sodium-independent manner. Oat8 interacted with chemically heterogenous anionic compounds but not with the organic cation TEA. Oat8mediated ES transport was inhibited by several sulfate conjugates, whereas glucuronide conjugates showed no inhibitory effects. Oat8 protein is localized in the collecting ducts.
OAT9: In a mouse EST database search, we found one EST clone that showed significant identity to OATs (52) . This gene product shows approx. 36% identities to other OATs. Expression of OAT9 mRNA has been detected only in the kidney and brain. For functional analysis, we used proximal tubule cells (S2 cells) stably expressing OAT9. OAT9 mediated transport of nicotinic acid, salicylic acid, and PGE 2 .
OAT-PG: In the kidney, prostaglandins (PGs), especially PGE 2 , have important roles in renal hemodynamics, renin release, and tubular sodium and water reabsorption. Since PGs are charged organic anions at physiological pH, it is difficult for them to penetrate biological membranes. Accordingly, PG transport is a carrier-mediated process. So far, only prostaglandin transporter (PGT) from the OATP (SLC0 / SLC21) family has been shown to be a transporter specific to PGs. We isolated a cDNA encoding a novel prostaglandin-specific transporter from the mouse kidney (53) . Since this transporter belongs to the OAT family (SLC22) and is structurally distinct from PGT, we named it prostaglandin-specific organic anion transporter (OAT-PG). OAT-PG specifically mediated transport of PGs such as PGE 2 and PGF 2α . OAT-PG mRNA is expressed exclusively in the kidney. We speculate that OAT-PG plays an important role in renal handling of PGE 2 and contributes to physiological functions involved in PGE 2 metabolism and signaling in the distal segments of nephrons.
Regulations
Phosphorylation
Organic anion transport in intact renal proximal tubular cells in animal model systems is downregulated by protein kinase C (PKC). All OAT isoforms cloned have several sites for PKC phosphorylation in the large intracellular loop between the sixth and seventh transmembrane domains. Several studies have revealed that the activation of PKC decreases the transport activity of OATs (54 -59) . This inhibitory effect is also associated with altered substrate selectivity. The reduced OATmediated transport activity is rescued by PKC inhibitors (54, 55) . Furthermore, PKC-induced hOAT1 downregulation is achieved via carrier retrieval from the cell membrane (58) . In addition to the sites for phosphorylation by PKC, OAT isoforms have putative sites for phosphorylation by protein kinase A (PKA), casein kinase II, or tyrosine kinase. Among these, protein kinases, including mitogen-activated protein kinase (MAPK), PKA, and tyrosine kinase, have been shown to be involved in the regulation of OAT transport functions (59 -61) . Epidermal growth factor (EGF) stimulates PAH and estrone sulfate transport in rabbit renal proximal tubules via MAPKs, and PGE 2 enhances basolateral PAH and estrone sulfate uptake via adenylate cyclase activation and causes PKA activation (59, 60) . A recent study has demonstrated that OAT3-mediated activity is also inhibited by tyrosine kinase and phosphatidylinositol 3-kinase (PI3K) (61).
Glycosylation
Glycosylation sites in the first extracellular loop between transmembrane domains (TMDs) 1 and 2 are conserved in OATs. Tunicamycin, an inhibitor of asparagine-linked glycosylation, inhibited PAH transport activity in mOat1-transfected COS7 cells (62) . Immunofluorescence revealed that the mOat1 protein remained mainly in the intracellular compartment after tunicamycin treatment (62) . That study indicates that glycosylation of the mOat1 protein is necessary for proper trafficking of the protein to the plasma membrane. Other experiments have demonstrated that disruption of Asp39 (one of the glycosylated sites) in mice resulted in complete loss of transport activity of OAT1 without affecting its surface expression (63) . Thus, glycosylation could also be responsible for substrate recognition.
Recently, Zhou et al. investigated how the addition / acquisition and processing / modification of N-linked oligosaccharides play a role in the functional maturation of OAT4 using a novel approach (64) . Inhibition of acquisition of oligosaccharides in OAT4 by mutating Asn to Gln and by tunicamycin treatment was combined with wild-type OAT4 expression in a series of mutant CHO-Lec cells defective in different steps of glycosylation processing. Zhou et al. demonstrated that both the disruption of glycosylation sites by mutagenesis and the inhibition of glycosylation by tunicamycin treatment resulted in a nonglycosylated OAT4, which was unable to target to the cell surface. In contrast, OAT4 synthesized in mutant CHO-Lec cells carrying different structural forms of sugar moieties (mannose-rich in Lec1 cells, sialic acid-deficient in Lec2 cells, and sialic acid/ galactose-deficient in Lec8 cells) was able to traffic to the cell surface. However, OAT4 expressed in CHO-Lec1 cells had significantly lower binding affinity for its substrates than did that expressed in parental CHO cells. These results provided novel information that addition / acquisition of oligosaccharides but not the processing of added oligosaccharides participates in the membrane insertion of OAT4. Processing of added oligosaccharides from mannose-rich type to complex type is important for enhancing the binding affinity of OAT4 for its substrates. Glycosylation could therefore serve as a means to specifically regulate OAT4 function in vivo.
Transcriptional regulation
Eraly et al. (65) investigated regulatory elements using comparative genomics approaches. Binding sites for transcription factors, including PAX1, PBX, WT1, and HNF1, are present within the evolutionarily conserved noncoding sequences of OATs, although the roles of these transcription factors in expression of OATs have not been clarified.
The cloning and preliminary characterization of a human urate transporter (hURAT1) gene promoter was reported by Li et al. (66) . The transcription initiation site was mapped to a base 337-bp upstream of the ATG start codon by primer extension and 5'-RACE. The minimal functional promoter region was within 253 bp when promoter/ luciferase constructs were transfected into OK cells. Testosterone significantly increased promoter activity, suggesting that hormonal regulation of hURAT1 is the cause of gender differences in blood urate levels.
Recently, cis-acting elements in the 5'-flanking region that regulate hOAT2 transcription were characterized by Popowski et al. (67) . A consensus binding motif for the hepatocyte nuclear factor-4α (HNF-4α) is located at nucleotides −329/ −317 relative to the transcription initiation site. A luciferase-linked hOAT2 promoter fragment containing the HNF-4α binding site was transactivated with co-expression of HNF-4α in Huh7 cells, whereas site-directed mutagenesis of the DR-1 element abolished activation by HNF-4α. SiRNAs inhibiting endogenous HNF-4α expression markedly reduced endogenous hOAT2 expression in Huh7 cells. Since HNF-4α is a known target for bile acid-mediated repression of gene transcription, Popowski et al. investigated whether chenodeoxycholic acid (CDCA) sup-presses hOAT2 gene expression by inhibiting HNF-4αmediated transactivation. Treatment of Huh7 cells with CDCA or the synthetic farnesoid X receptor (FXR) agonist GW4064 decreased mRNA and protein levels and also nuclear binding activity of HNF-4α. The FXRinducible transcriptional repressor small heterodimer partner inhibited transactivation of hOAT2 promoter constructs and of endogenous hOAT2 expression by HNF-4α. They concluded that the hOAT2 gene is critically dependent on HNF-4α and that bile acids repress the hOAT2 gene by inhibiting HNF-4α. Hepatic uptake of hOAT2 substrates may thus be decreased in disease conditions associated with elevated intracellular levels of bile acids.
Gender differences
Gender differences in mRNA and / or protein expression have been reported for Oat1 (68, 69) , Oat2 (69 -71), Oat3 (68, 69, 71) , and Urat1 (72), suggesting that some OAT family members are regulated by sex hormones. The mouse Oat1 mRNA levels were found to be higher in the male kidney than in the female kidney, and the rat Oat2 mRNA expression level was found to be higher in the female kidney than in the male kidney or liver. In contrast, the mouse Oat2 mRNA levels were found to be high in both male and female kidneys and low in the male liver. Rat Oat3 mRNA expression was detected in the male liver. The mouse Urat1 mRNA levels were found to be higher in the male kidney than in the female kidney.
Ontogenic expression
Developmental changes in expression of OATs have been reported (69, 73, 74) : the mRNA expression levels of Oat1, Oat2, and Oat3 increased during postnatal development.
Pathophysiological status
Recent studies have indicated that the expressions of OATs are affected in pathophysiological states. During the progression of renal insufficiency, various uremic toxins derived from dietary proteins accumulate in uremic plasma. Many uremic toxins are organic anions; their accumulation in the kidney is a result of renal dysfunction, and this also accelerates underlying renal diseases. Enomoto et al. (75) demonstrated that the administration of indoxyl sulfate (IS) into nephrectomized rats enhanced the progression of chronic renal failure. Immunohistochemical studies revealed that the amount of IS in proximal tubular cells and the expression of OAT1 and OAT3 are both increased in a chronic renal failure model. Deguchi et al. (76) analyzed the transport of various uremic toxins, such as IS, 3-carboxy-4-methyl-5-propyl-2-furanpropionate, indole acetate, and hippurate, via OAT1 and OAT3. They showed that rOat1 / hOAT1 and rOat3 / hOAT3 play major roles in the renal uptake of these uremic toxins. The enhanced expression of OATs in uremic circumstances indicates compensatory effects for elimination of uremic substrances and leads to progress of the underlying diseases by accumulation of harmful uremic toxins in proximal tubular cells. The expressions of OATs are affected by several renal dysfunction models. Bilateral urethral obstruction in adult male rats decreases Oat1 and Oat3 expression levels in basolateral membrane fractions in the kidney (77) . Acute arterial calcinosis induced by bolus injection of vitamin D3 also increases the Oat1 expression level (78) . OAT expression in various human kidney diseases, was analyzed using a real-time PCR method (79) . The data indicate that OAT3 expression is decreased in patients with renal diseases. OAT expression is influenced not only by renal diseases but also by hepatic diseases. A compensatory enhancement of organic anion excretion in rats with acute biliary obstruction was demonstrated for OAT1 and OAT3 (80) . In a rat model of fever generation in which peripheral PGE 2 is increased and clearance by metabolism of peripheral PGE 2 is downregulated, PGE 2 not only timedependently downregulates basolateral organic anion uptake but also diminishes expression of both rOat1 and rOat3 (81) . These results suggest that during fever or inflammation, renal secretory transport of PGE 2 is reduced, contributing to elevated PGE 2 levels in blood. The significance and relevance of changes in OAT expression in pathophysiological states are an important issue for future studies.
Structure-function relations
Site-directed mutagenesis studies revealed that the following residues are important for substrate recognition: His34, Lys394, and Arg478 in flounder Oat1 (82) and Lys370 and Arg454 in rOat3 (83) . Recently, information regarding functionally critical amino acid residues has been increasing.
OAT1: An alanine scanning mutagenesis study revealed that residues Leu-30 and Thr-36 are important for OAT1 transport activities (84) . Progressively smaller side chains at position 30 increasingly impaired hOAT1 function mainly because of the impaired surface expression of the transporter. Substitution of Thr-36 by serine and cysteine at this position abolished transport activity without affecting the surface expression of the transporter. These results indicate that both the methyl group and the hydroxyl group of Thr-36 could be critical for hOAT1 activity.
The cysteine-modifying reagent p-chloromercuri-benzenesulphonate (PCMBS) inhibits mOat1-mediated PAH transport in HeLa cells (85) . Site-directed mutagenesis studies revealed that single replacement of cysteine residues had no significant effect on mOat1mediated PAH transport but that multiple replacements in the C-terminal region (C335 / 379 / 427 / 434A; Cys335 / 379/ 427/ 434Ala) resulted in a substantial decrease in transport activity. A simultaneous replacement of all 13 cysteine residues (C-less) led to a complete loss of transport function. The decrease in or lack of transport activity of the mutants C335 / 379 / 427 / 434A and C-less was due to the impaired trafficking of the mutant transporters to the cell surface. These results suggest that although cysteine residues are not required for function in mOat1, their presence appears to be important for targeting of the transporter to the plasma membrane. Since C49A was less sensitive than the wild-type mOat1, the modification of Cys49 may play a role in the inhibition of mOat1 by PCMBS.
Hong et al. first demonstrated that hOAT1 exists in the plasma membrane as a homooligomer (86) . They investigated the quaternary structure of hOAT1 using combined approaches of chemical cross-linking, gel filtration chromatography, co-immunoprecipitation, cell surface biotinylation, and metabolic labeling.
OAT4: The histidine-modifying reagent diethyl pyrocarbonate (DEPC) inhibitied OAT4-mediated estrone sulfate transport in COS-7 cells (87) . Single replacement of His (H)-47 or simultaneous replacement of H47 / 52/ 83 or H47 / 52/ 83/ 305 / 469 to Ala by sitedirected mutagenesis led to a 50% -80% decrease in transport activity. The decreased transport activity of these mutants was correlated with a decreased amount of cell surface expression. These results suggest that mutation at positions 47, 47 / 52 / 83 and 47 / 52 / 83 / 305 / 469 impaired membrane expression rather than function. Since H469A mutant lacks sensitivity to DEPC inhibition, the modification of His-469 seems to be responsible for the inhibition of OAT4 by DEPC.
The role of conserved glycine residues in OAT4 function was investigated by Zhou et al. (88) . Mutants G11S, G383S, G388S, and G466S exhibited transport activities comparable with those of wild-type OAT4, while mutants G241S and G400S had almost completely lost transport function. They then demonstrated that increasingly larger side chains at positions 241 and 400 increasingly impaired OAT4 function. Cell-surface biotinylation showed that mutations of Gly-241 and Gly-400 interfered with the trafficking of the transporter to the cell surface. Substitutions of amino acids with large side chains at positions 241 and 400 resulted in decreased V max and increased K m . These results suggest that Gly-241 and Gly-400 are important both in targeting the transporter to the plasma membrane and in substrate binding.
Targeted disruption
The generation of gene knockout animals could provide new information on the contribution of individual transporters in intact organs. Knockout mice for Oat1 (89) and Oat3 (26) have been generated. Both models revealed the loss of organic anion transport and indicated the importance of drug uptake of Oat1 in the kidney (89) and of Oat3 in kidney (26) and choroids plexus (90) , although they showed no morphological changes.
Drug-drug interactions
Drugs present in plasma could affect the transport of the drugs individually and could mutually influence the pharmacokinetics of the drugs. A notable example is the concomitant use of probenecid and penicillin G; the half-life of penicillin G is significantly prolonged when combined with probenecid compared with when it is administered alone. It has also been reported that the administration of methotrexate (MTX) with acidic drugs, such as NSAIDs, and β-lactam antibiotics causes severe suppression of bone marrow. NSAIDs and βlactam antibiotics inhibit the tubular secretion of MTX, thereby reducing its renal clearance. As a consequence, unwanted side-effects, such as bone marrow suppression, could occur as a result of the increase in plasma MTX levels (91, 92) . An extensive review on OATmediated drug-drug interactions is available (93).
Polymorphisms
In addition to drug-metabolizing enzymes, drug transporters play important roles in determining the pharmacokinetic profiles of drugs and their pharmacological effects. Recent wide-scale sequencing analysis of the human genome has lead to identification of the single nucleotide polymorphisms (SNPs) of drug transporters. It has been suggested that drug transporter SNPs are responsible for the interindividual variation in drug elimination from the body (94) . Recently, two groups reported results of functional analysis of non-synonymous variants of hOAT1 genes (95, 96) . Fujita et al. found six non-synonymous variants of hOAT1 (95) . Two variants (R50H and R293W) exhibited normal uptake of PAH, ochratoxin A, and methotrexate assayed in Xenopus oocytes. One variant, R454Q, was nonfunctional with respect to the above substrates. In a clinical study, no significant decrease was found between renal secretory clearance of adefovir in family members heterozygous for hOAT1-454Q and in those with the reference transporter, hOAT1-454R. Bleasby et al. found twenty hOAT1 SNPs from genomic DNA from 92 individuals of African, Asian, and Caucasian origin (96) . Among them, two SNPs encoded changes in the amino acid sequence: R50H and K293I. These SNPs were only present in samples of African origin. When expressed in Xenopus oocytes, wild-type R50-hOAT1 and the variants R50H-hOAT1 and K525I-hOAT1 all mediated probenecid-sensitive PAH uptake. Kinetic analysis indicated that the transport affinity (K m ) for PAH was unchanged in the variants compared with that in the wild type. Interestingly, the Km for the nucleoside phosphonate analogs adefovir, cidofovir, and tenofovir seemed to be decreased in the R50H variant compared with that in the wild type, whereas the kinetics of K525I remained unchanged. Studies on human drug transporter SNPs have been started, and accumulation of such information should lead to the establishment of individualized drug therapy in the future.
Protein-protein interaction
It has been demonstrated that several transporters located in the apical membrane of proximal tubular cells possess a PDZ motif at their COOH-terminal end (6, 97) . The PDZ motif is one of the protein-protein interaction modules and is composed of three amino acid residues: S/ T-X-Φ (where X is any amino acid and Φ is a hydrophobic residue). The renal apical organic anion transporters OAT4 and URAT1 possess the PDZ motif at their C-terminus. Yeast two-hybrid experiments revealed that both OAT4 and URAT1 interact with the multivalent PDZ domain-containing protein PDZK1 via their C-terminal PDZ motifs (98, 99) . The coexpression of URAT1 / OAT4 and PDZK1 in HEK293 cells increases URAT1/ OAT4 transport activity. This synergic effect is abolished when the C-terminal PDZ motif deletion mutant of URAT1 / OAT4 is coexpressed with PDZK1. These results indicate that PDZK1 regulates transport activities via interaction with the PDZ motif.
To date, four PDZ proteins, Na + / H + exchanger regulatory factor (NHERF)1, NHERF2, PDZK1 (NHERF3), and intestinal and kidney-enriched PDZ protein IKEPP (NHERF4), have been identified in the apical membrane of renal proximal tubular cells (97) . We also found that OAT4 interacts with NHERF1 and that the coexpression of OAT4 and PDZK1 in HEK293 cells increases OAT4-mediated estrone sulfate transport activity (99) . NHERF1 and PDZK1 have been shown to interact with several organic anion transporters such as Na + -dependent phosphate cotransporter type 1 (NPT1), MRP2, and MRP4. Since PDZK1 and NHERF1 can bind to each other, both PDZK1 and NHERF1 may organize the scaffold network and tether several apical transporters simultaneously in the apical membrane of renal proximal tubular cells.
In kidneys, the proximal tubule has important roles in both the reabsorption of filtered substances and the secretion of water-soluble drugs, toxins, and metabolic waste products. These two opposite transport directions are simultaneously accomplished by the coordinated action of ion channels and transporters located both in the apical membrane and basolateral membrane. Thus, the polarized expression of these membrane proteins is essential for the function of proximal tubular cells. Scaffolding proteins underneath the plasma membrane, such as PDZ proteins, are thought to contribute to the generation of cell polarity by the formation of a junctional complex and by protein anchoring. In addition, proximal tubular transport processes are regulated by a number of factors, including hormones such as parathyroid hormone. For efficient and specific signal transduction, for the enhancement of membrane expression, and for the direct modulation of transport processes, the formation of functional complexes, including transport proteins, hormonal receptors, and intracellular signaling elements, is beneficial. This supramolecular structure, namely "Transportsome", supported by scaffolds such as PDZ proteins, is proposed to be an ultimate functional unit of membrane transport.
Besides PDZ proteins, a novel protein that modulates transporter activities has been identified. A new ischemia / reperfusion-inducible protein (IRIP), which belongs to the SUA5 / YrdC / YciO protein family, was isolated in a differential display analysis of an ischemia / reperfusion-treated kidney RNA sample (100). Mouse IRIP mRNA was expressed in all tissues tested, the highest levels being in the testis and in secretory and endocrine organs. Besides ischemia / reperfusion, endotoxemia also activated the expression of IRIP in the liver, lung, and spleen. The transporter regulator RS1, which was originally isolated from an expression cDNA library of porcine kidney cortex by screening the library with a monoclonal antibody that stimulated high-affinity phloridzin binding, was identified as an IRIP-interacting protein in yeast two-hybrid assays and coimmunoprecipitation assays. IRIP overexpression inhibited endogenous 1-methyl-4-phenylpyridinium (MPP + ) uptake activity in HeLa cells. The activities of exogenous organic cation transporters (OCT2 and OCT3), organic anion transporter (OAT1), and monoamine transporters were also inhibited by IRIP. IRIP is thought to regulate the activities of a variety of transporters under normal and pathological conditions.
Protein-lipid interaction
Localization is a major issue for membrane proteins, since their recruitment to the plasma membrane is a prerequisite for various functions of the proteins. Within the plasma membrane, correct localization is equally important, since a recent study has shown that the membrane itself is highly organized into lipid domains that provide subcompartments. These small (<100 nm) membrane domains, also called rafts, are enriched in sphingolipids and cholesterol and incorporate GPIanchored proteins, specific transmembrane proteins, and doubly acylated proteins such as tyrosine kinases of the Src family. Rafts have been proposed to function as platforms for the assembly of cytoplasmic and membranous signaling molecules and for polarized membrane traffic. Caveolae represent a subpopulation of lipid rafts that contain the scaffolding protein caveolin, which can organize the assembly of macromolecular complexes and regulate protein function within caveolae (101) . Three caveolin genes (Cav-1, Cav-2, and Cav-3) have been identified. Cav-1 and Cav-2 have a wide distribution among different cell types, whereas Cav-3 is expressed exclusively in all types of muscle. Since caveolin (Cav) is known to play a role in membrane transport, interactions between transporters and caveolins are an important issue. Kwak et al. demonstrated that rOat1 and Cav-2 are co-expressed in the plasma membrane and that rOat1's function for organic anion transport is upregulated by Cav-2 in physiological conditions (102) . Kwak et al. also showed that rOat3 and Cav-1 share cellular expression in the plasma membrane and that Cav-1 upregulates the organic anion uptake via rOat3 under physiological conditions (103).
Novel aspects of OATs
Recently, receptors for dicarboxylates such as succinate and α-ketoglutarate have been identified in the kidneys (104) . Succinate is a natural ligand for GPR91, and α-ketoglutarate is a natural ligand for GPR99, orphan G-protein-coupled receptors (GPCRs) in proximal and distal tubules. He et al. showed that succinate increases blood pressure in mice and that the succinateinduced hypertension involves the renin-angiotensin system. These findings suggest that the level of dicarboxylates surrounding proximal tubular cells, determined by the balance between the uptake of dicarboxylates via Na + -dependent dicarboxylate transporters (NaDCs) (105) and their efflux via OATs, is an important factor that regulates renovascular hypertension. In the earlier part of this review, we proposed by taking into account the existence of the outwardly directed dicarboxylate gradient in tubular cells that OAT4 contributes to the tubular reabsorption of organic anions. However, not only the organic anion influx but also the dicarboxylate efflux seems to have important roles for OAT family members, because no other transport protein mediating dicarboxylate efflux has been identified to date. Due to the function of apical organic anion-transporting multimolecular complex (organic anion transportsome), dicarboxylates remaining in the tubular fluid go down to the distal nephron and function as a signaling molecule for renovascular hypertension, a disease closely linked to atherosclerosis, diabetes, and renal failure. Therefore, apical organic anion transportsome can function as a regulator of dicarboxylate signaling and it could be a novel therapeutic target for the above-stated diseases (Fig. 3) .
The role of the efflux pathway for OATs seems also to be important in endocrine tissues. It has been suggested that OAT1 is involved in cortisol release from bovine and rat adrenal zona fasciculata cells, but there is no information on the existence of OATs in human adrenal cells. Asif et al. addressed the question of whether OATs are present in human adrenal cortical cells using the human adrenal cell line NCI-H295R established in 1990 from a patient with adrenocortical carcinoma who showed high rate of secretion of mineralcorticoids, glucocorticoids, and androgen (106) . RT-PCR did not reveal expression of hOAT1 and hOAT2, but hOAT3 and hOAT4 mRNAs were detected in both NCI-H295R cells and human adrenal tissue. When human OAT3 (hOAT3) and hOAT4 were expressed in Xenopus oocytes, only hOAT3 showed [ 3 H]cortisol uptake in excess of that of water-injected control oocytes. In NCI-H295R cells, [ 3 H]estrone sulfate uptake was saturable, cis-inhibited by OAT substrates, and transstimulated by preloading with glutarate or cortisol. Likewise, [ 3 H]PAH uptake was cis-inhibited by estrone sulfate and trans-stimulated by preloading the cells with PAH, glutarate, or cortisol, indicating functional expression of OATs in the plasma membrane of NCI-H295R cells. Therefore, in addition to the well known role of OATs in the elimination of organic anions from the body, the maintenance and regulation of endocrine functions would be another important role of them.
Perspectives
In this review, we describe recent progress in the understanding of various aspects of the OAT family (SLC22). Characterization of the OAT family members has brought us a step further in the elucidation of molecular mechanisms for drug elimination and distribution in the kidneys, liver, and brain. Nonetheless, many questions remain to be answered. First, several uncharacterized (orphan) transporters in the SLC22A superfamily remain, and further investigation is therefore required to determine their functions. Second, knowledge of the mechanisms by which OATs are regulated is lacking. Gender differences in the expression levels of OAT family members are of significant interest. Third, clarification of the three-dimensional (3D) structures of OATs is necessary to understand the broad substrate recognition of OATs. Because of difficulties in the purification and crystallization of membrane transporter proteins, the 3D structures of transporters have yet to be clarified. Fourth, a comprehensive understanding of the apical exit pathway for organic anions in the kidneys and the PDZ interaction on apical OATs is an important issue. Finally, the pathological significance of OATs is of great interest. Originally, studies on OATs were focused on the molecular mechanisms that underlie the elimination of xenobiotics. However, recent studies have unveiled the reabsorptive roles of endogenous compounds, such as urate, for OAT isoforms. This implies that the fundamental roles of OATs are not restricted to pharmacological and toxicological roles. Thus, genetic defects of OATs might give rise to pathophysiological states.
